Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Interesting article re: Forgent JPEG patent

See the Dutton report for Forgent below which was posted by xsthis on RB.  The judge in their case decided not to stay the litigation just to wait on an answer from the USPTO.  I wonder who the judge is and the venue for the litigation?

NOTE TO EDITORS: The following is an investment opinion issued
by Dutton Associates
EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Dutton Associates updates its coverage of Forgent Networks (Nasdaq:FORG), maintaining a Speculative Buy rating and a target price of $2.00. The 11-page report by Dutton senior analyst Richard West, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals.

Forgent Networks' successful program of licensing its intellectual property, generated revenue of more than $122.0 million in fees over the past five years. Since our October 10, 2006, Research Report, Forgent’s Intellectual Property program has suffered some setbacks and is now waiting upon possible settlements in the outcome of the pending trial for the ‘746 patent. In the face of the uncertainty surrounding the ‘746 Patent litigation, we lowered our rating to Neutral on December 1, 2006. However, considering Forgent’s cash position, the Court’s denial of a motion to stay the ‘746 Patent litigation pending the outcome of the US Patent Office re-examination of the ‘746 Patent, its maintaining listing on the NASDAQ Global Market Exchange, and that its common stock has moved up from the first of December price of $0.50 per share to its current level of $1.60 per share on heavy volume (3.2 million daily average shares in the month of December), we reiterate our January 3rd rating of Speculative Buy with a 12-month price target being set at $2.00 per share.
We caution investors to consider the risks of the unknown results from the ‘746 Patent litigation, which is scheduled for trial in May 2007.

Share
New Message
Please login to post a reply